Abstract:e24281 Background: Targeted therapy for patients of NSCLC with HER2 mutations is still on unmet need in clinical setting. Pyrotinib, a HER2 and EGFR tyrosine kinase inhibitor, has showed encouraging anti-tumor effect with a ORR of 54.5% (6/11) in our preliminary data of phase 2 trial. This study aimed to investigate the anti-cancer effect and the potential different mechanism of pyrotinib in organoids and PDX models with HER2 mutation, compared with the other anti-HER2 drugs, afatinib and T-DM1. Methods: Organoids and PDX models were established from the therapeutic naïve patient with HER2-mutant lung cancer. Anti-tumor efficacy,and downstream signaling pathways inhibition were analyzed and compared in afatinb, T-DM1 and different dose of pyrotinib groups in both the organoids and PDX models. Results: Patient-derived organoids and xenografts were established from a 42-year-old female with HER2-A775_G776YVMA-inserted advanced lung adenocarcinoma. When the organoids were treated with afatinib and pyrotinib, at 29nM and 180nM respectively(adopted from the plasma concentrations of previous phase 1 clinical trials) , pyrotinib significantly inhibited the cell growth compared with afatinib(p = 0.0038). The in vivo PDX model study showed that pyrotinib(mouse,80mg/kg,adopted from clinical trial recommended dose) showed a significantly superior anti-cancer effect than afatinib of 15 mg/kg (p = 0.0471), T-DM1 of 10 mg/kg (p = 0.0138) and lower dose of pyrotinib 5 mg/kg(p = 0.0001) and 20 mg/kg(p < 0.0001). Pyrotinib(80mg/kg) also showed a robust ability to inhibit pHER2, pERK and pAkt both in the IHC and western blot analysis. Meanwhile, the body weight of PDX model mice receiving afatinib of 15mg/kg showed a significantly decrease compared with pyrotinib of 80mg/kg(p < 0.0001). Conclusions: Pyrotinib, afatinb and T-DM1 all showed the ability to inhibit HER2 in lung cancer models, while pyrotinib showed a significantly better tolerance and anti-cancer effect than afatinib and T-DM1, which might contribute the encouraging results of our previous phase 2 trial.

A Thiopyran Derivative with Low Murine Toxicity with Therapeutic Potential on Lung Cancer Acting Through a NF-κB Mediated Apoptosis-to-pyroptosis Switch.

Pyroptosis: A Promising Target for Lung Cancer Therapy

Design and Optimize N-substituted EF24 as Effective and Low Toxicity NF-κB Inhibitor for Lung Cancer Therapy via Apoptosis-to-Pyroptosis Switch.

Comparison the Anti-Tumor Effect of Pyrotinib, Afatinb and T-DM1 in Lung Cancer Organoids and PDX Models with HER2 Mutation.

A novel monocarbonyl analogue of curcumin, (1E,4E)-1,5-bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway.

Rational Design, Synthesis, and Pharmacological Characterisation of Dicarbonyl Curcuminoid Analogues with Improved Stability Against Lung Cancer Via ROS and ER Stress Mediated Cell Apoptosis and Pyroptosis.

Pyroptosis in cancer treatment and prevention: the role of natural products and their bioactive compounds

Biomimetic Nanoparticle Synchronizing Pyroptosis Induction and Mitophagy Inhibition for Anti-Tumor Therapy.

Piperlongumine Analogue L50377 Induces Pyroptosis Via ROS Mediated NF-κB Suppression in Non-Small-cell Lung Cancer.

A Novel Pharmacological Mechanism of Anti-Cancer Drugs That Induce Pyroptosis

Targeting pyroptosis in breast cancer: biological functions and therapeutic potentials on It

Pyroptosis induced by natural products and their derivatives for cancer therapy

Devising Biocompatible, NIR-Activated Helical Pyroptosis Agents via 𝛑-Twisting Strategy for Promoting Antitumor Immunity

Synthesis and Biological Evaluation of a Novel Apogossypolone Derivative

Pyroptosis: shedding light on the mechanisms and links with cancers

Pyroptosis and the fight against lung cancer

New Prospects of Cancer Therapy Based on Pyroptosis and Pyroptosis Inducers

An expedient multi‐component synthesis of pyridinyl‐spirooxindoles and their effect on proliferation of lung cancer A549 cells

Devising Biocompatible, NIR‐Activated Helical Pyroptosis Agents via π‐Twisting Strategy for Promoting Antitumor Immunity

Discovery of 1,3,4-Oxadiazole Derivatives As Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Epigenetics-Based Tumor Cells Pyroptosis for Enhancing the Immunological Effect of Chemotherapeutic Nanocarriers.